TrendRadars > Science > Apotex Recalls Brimonidine Tartrate Ophthalmic Solution
Apotex Recalls Brimonidine Tartrate Ophthalmic Solution
Apotex Recalls Brimonidine Tartrate Ophthalmic Solution,Weston, Florida-based Generic drug maker Apotex Corp. is initiating a recall for six lots of Brimonidine Tartrate Ophthalmic Solution, 0.15% at the consumer level, the U.

Apotex Recalls Brimonidine Tartrate Ophthalmic Solution

Weston, Florida-based Generic drug maker Apotex Corp. is initiating a recall for six lots of Brimonidine Tartrate Ophthalmic Solution, 0.15% at the consumer level, the U.S. Food and Drug Administration said. The recall was initiated due to cracks that have developed in some of the units caps of the bottles.

There is a possibility that the broken cap may impact sterility and if so, the possibility of adverse events.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure or IOP in patients with open-angle glaucoma or ocular hypertension.

The affected Brimonidine Tartrate Ophthalmic Solution, 0.15% comes in 5 ml, 10 ml, and 15 ml packs. The 5 ml packs comes with lot #TJ9848 and TJ9849 with expiry date 02/2024, and lot # TK0258 and TK5341 with expiry date of 04/2024.

Further, 10 ml packs comes with lot# TK0261 and expiry date of 04/2024, and 15 ml packs with lot#TK0262 and expiry date of 04/2024.

These affected lots were distributed nationwide in the United States between April 05, 2022 to February 22, 2023.

Consumers, wholesalers, distributors, warehousing chains, mail order pharmacy and long-term care pharmacy are urged to return the recalled product to the place of purchase.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News